Compare · LLY vs PBYI
LLY vs PBYI
Side-by-side comparison of Eli Lilly and Company (LLY) and Puma Biotechnology Inc (PBYI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and PBYI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 2557.5x PBYI ($434.2M).
- Over the past year, LLY is up 52.7% and PBYI is up 150.7% - PBYI leads by 98.0 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 5 for PBYI).
- LLY has more recent analyst coverage (25 ratings vs 4 for PBYI).
- Company
- Eli Lilly and Company
- Puma Biotechnology Inc
- Price
- $1178.57+0.73%
- $8.53+1.25%
- Market cap
- $1.11T
- $434.2M
- 1M return
- +5.00%
- +18.73%
- 1Y return
- +52.71%
- +150.74%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 5
- Recent ratings
- 25
- 4
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend
Latest PBYI
- President and CEO Auerbach Alan H sold $364,051 worth of shares (44,058 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 0.60% to 7,261,671 units (SEC Form 4)
- Officer Hunt Douglas M sold $69,905 worth of shares (8,460 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 196,841 units (SEC Form 4)
- Chief Financial Officer Nougues Maximo F sold $77,557 worth of shares (9,386 units at $8.26) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 230,637 units (SEC Form 4)
- SEC Form 144 filed by Puma Biotechnology Inc
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wilson Troy Edward was granted 27,000 shares and sold $77,748 worth of shares (10,800 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 37% to 59,750 units (SEC Form 4)
- Director Stuglik Brian M was granted 27,000 shares and sold $58,311 worth of shares (8,100 units at $7.20) as part of a pre-agreed trading plan, increasing direct ownership by 20% to 113,858 units (SEC Form 4)
- Director Senderowicz Adrian sold $194,311 worth of shares (27,000 units at $7.20) as part of a pre-agreed trading plan and was granted 27,000 shares (SEC Form 4)
- Director Miller Michael Patrick was granted 27,000 shares, increasing direct ownership by 50% to 81,000 units (SEC Form 4)